Comparação de instrumentos de avaliação neuropsicológica para a demência grave by Wajman, José Roberto & Bertolucci, Paulo Henrique Ferreira
Arq Neuropsiquiatr 2006;64(3-B):736-740
Hospital São Paulo, Setor de Neurologia do Comportamento - Disciplina de Neurologia - Escola Paulista de Medicina - UNIFESP -
São Paulo SP, Brasil.
Received 27 January 2006, received in final form 15 May 2006. Accepted 9 June 2006.
Dr. José Roberto Wajman - Disciplina de Neurologia / Escola Paulista de Medicina / UNIFESP - Rua Botucatu 740 - 04023-900 São
Paulo SP - Brasil. E-mail: betowajman@usa.com
COMPARISON BETWEEN NEUROPSYCHOLOGICAL 
EVALUATION INSTRUMENTS FOR SEVERE DEMENTIA
José Roberto Wajman, Paulo Henrique F. Bertolucci
ABSTRACT - Objective: To study the correlation between two tools for cognitive evaluation, Mini-Mental
State Examination-severe (MMSE-s) and Severe Impairment Battery (SIB), and the Bristol Daily Activities
Functional Scale. Method: 50 patients from the Behavioral Neurology Section - EPM-UNIFESP - were eval-
uated. Mean age was 76.8±7.9 (range 57 to 95); 32% were males; mean education was 5.0±2.3 years (range
4 to 15); mean disease duration was 3.9±1.5 years (range 2 to 10). Results: Preliminary results in a small
sample drawn from the study group do indicate a difference between the three cognitive scales. SIB and
MMSE-s had a better correlation with functional score than MMSE, and MMSE-s had a correlation slight-
ly better than SIB. Conclusion: These data indicate that it is possible to follow dementia patients up to
severe stage as long as adequate instruments are used, and that there may be differences between scales
with regard to sensitivity. 
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Comparação de instrumentos de avaliação neuropsicológica para a demência grave
RESUMO - Objetivo: Avaliar a correlação entre dois instrumentos de avaliação cognitiva, o Mini-Exame do
Estado Mental-grave (MEEM-g) e a Bateria para Comprometimento Grave (SIB), e compara-los com a Escala
Funcional de Atividades Diárias Bristol. Método: Foram avaliados 50 pacientes provenientes do Setor de
Neurologia do Comportamento - UNIFESP-EPM - com idade entre 57 e 95 anos (média 76,84 anos, desvio-
padrão 7,94 anos e mediana 77,00 anos); 16 (32,0%) eram do sexo masculino; tempo de escolaridade era
4 a 15 anos (média 5,08±2,31 anos e mediana 4,00 anos). Resultados: Foi possível observar aspectos de
sensibilidade entre o MEEM tradicional e os outros dois instrumentos de avaliação para fases avançadas.
Conclusão: É possível seguir acompanhando o paciente demenciado, mesmo em fases avançadas da doença,
em relação às avaliações cognitiva e funcional. 
PALAVRAS-CHAVE: testes cognitivos, escala funcional de atividades diárias, demência.
For a long time Alzheimer disease (AD) was con-
sidered a rare disorder and four or five decades ago
classical papers on this disease failed to mention
details of its clinical picture1. According to MedLine
only 42 papers with AD as a key word were published
in 1975 (compared with 1285 in the first 6 months of
2005). 
AD is the most common dementing disorder in
the elderly population. Typically this disorder has a
insidious onset, with progressive decline of memory,
followed by other cognitive areas, such as executive
function, language, and praxis2. It is estimated that
in the United States only more than four million eld-
erly have dementia at a severe stage and another
one and half million dementia at mild or moderate
stage. It is expected that the population with demen-
tia in that country will rise to nine million by 20303.
Investigations in São Paulo state hinterland showed
the same trend4, with an estimated 750 thousands
to one million Brazilians with dementia. The realiza-
tion of the huge dimension of AD has brought a lot
of interest in treating and following these patients
as they progress to more advanced disease stages.
Many scales have been developed for the evaluation
of pre-clinical, mild and moderate stages5, but the
same is not true for the evaluation of patients in mo-
re severe stage, for whom relatively few investiga-
tions have been undertaken6. 
The evaluation of cognitive abilities in these pa-
tients would fill several clinical and research needs,
like the identification of less affected cognitive areas,
which could in turn be used by health professionals
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as starting point for the development of compensa-
tory strategies; in the setting of normative data for
this population, useful not only in the follow up of
this group, but also in evaluating the effect of treat-
ment; in the investigation of the correlation between
post mortem neurochemical and neuropathological
changes and cognition. 
The development and application of standard-
ized and validated neuropsychological scales has had
a significative impact in improving diagnostic preci-
sion and in the characterization of the cognitive de-
cline associated with AD7, but, with disease progres-
sion, the use of most scales for neuropsychological
evaluation is hampered by the floor effect, with per-
formance near null. Patients are considered as “non
testable” when their neuropsychological perform-
ance is much under the lower limit, indicating that
there is a severe cognitive decline, but, even at a very
advanced stage, there might be cognitive areas that
are spared. There is ample justification for the state-
ment that little is known about more cognitively and
functionally affected patients, in large part due to
the low sensitivity for this group of most of the scales
in common use.
Cognitive tests for patients in a more severe stage
were developed, like the Test for Severe Impairment
(TSI)8, the Modified Ordinal Scales of Psychological
Development9 (MOSPD) the Severe Cognitive Impair-
ment Profile (SCIP)10. Many of these scales took into
consideration the language difficulties of these pa-
tients, but for their administering special training and
specific material are needed. In the average, their
administration takes 40 minutes. These points sug-
gest the ideal scale should as much as possible: 1) cha-
racterize patients cognitive deterioration level and
disease progression; 2) sensitive and easily applica-
ble to the Brazilian population; 3) brief, but evalu-
ating as extensively as possible the cognitive func-
tions; 4) not needing extensive training and a large
load of technical resources; 5) be useful in longitudi-
nal follow up of pharmacological and non pharma-
cological treatment. 
To this end severe impairment battery (SIB) and
mini-mental state-examination-severe (MMSEs) were
developed for the evaluation of patients with severe
cognitive impairment non testable by the usual cog-
nitive scales11. By their very characteristics they might
disclose differences among severe stage patients that
are not identified by conventional scales. If this is
true, performance in these scales would correlate
more closely with functional status than convention-
al scales. This investigation was undertaken to com-
pare the performance in the MMSEs and SIB and the
performance in the Bristol Daily Activities Functional
Scale; stratification of CDR 2 and 3 patients by SIB
and MMSEs score; to compare the stratification by
these two scales and by MMSE; correlation between
SIB and MMSEs and age, education, and disease dura-
tion. 
METHOD
Fifty patients with probable AD (DSM-IV) in moderate
to severe stages (CDR 2 and 3) and a MMSE score of 15 or
less were included. All patients were recruited from out-
patient clinic (Behavioral Neurology Section - Federal Uni-
versity of São Paulo - São Paulo - Brazil) and had an unpaid
reliable informant. A written explanation of the research
design was read by the responsible for the patient and addi-
tional explanations were given when necessary, after which
an informed consent was signed. All proceedings were ap-
proved by the Institutional Review Board.
To be included patients had to have at least some de-
gree of verbal ability and sighting and hearing enough to
be evaluated. Neurological or psychiatric conditions that
could impact on cognition were exclusion criteria.
Evaluation was done in a single individual session with
mean duration of one and half hour. While SIB and MMSEs
were applied to the patient the informant filled the Bristol
scale. In half of the patients the order of application was
SIB and MMSEs and the reverse for the other half. 
Scales – Bristol Daily Activities Functional Scale12 is com-
posed by 20 questions to assess daily activities in a scale
ranging from 0 to 4, with a maximum score of 60. Since in-
capacity is scored, the higher the score the more the functio-
nal incapacity. The informant completed the scale, and any
doubts were discussed with the investigator.
The Mini-mental State Examination - severe is based on
the original MMSE but includes questions related to auto-
biographical knowledge, orientation, simpler comands,
constructional praxis, phonological loop, semantic verbal
fluency, and memory. The score ranges from 0 to 30 and,
like the original MMSE, is a pencil and paper test which,
takes a mean of 5 minutes to be completed.
The Severe Impairment Battery has 9 sub-items, evalu-
ating social interaction, orientation, visual spatial ability,
constructional praxis, language, attention, memory, orien-
tation to own name, and praxis. Cues and repetition of
commands are permitted and the score ranges from 0 to
100 (higher scores meaning better performance), there is
need of a kit of objects and mean time for the test com-
pletion is 25 minutes.
For the translation of SIB and MMSEs the following me-
thod was adopted: 1) translation by a professional famil-
iar with the scales; 2) translation review by bilingual peo-
ple with experience in psychogeriatrics; 3) revision by a
group representative of the population in which the scales
are used; 4) independent back translation; 5) evaluation of
the back translation by bilinguals with attention to signif-
icant differences in comparison with the original and review
of syntaxes and semantic aspects.
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In a preliminary step all variables went through a des-
criptive analysis. For quantitative variables minimum and
maximum scores were observed and medians, means, and
square deviation were calculated. For qualitative analysis
absolute and relative frequencies were calculated.
Non parametric Mann-Whitney test was used for the
comparison between groups, since normal distribution was
rejected. For the correlation of variables Spearman coeffi-
cient was used. Significance level was set at 5%.
RESULTS
Fifty patients with age ranging from 57 and 95
years (mean 76,84±7,94; median 77,00). Sixteen
(32,0%) patients were male. Disease duration ranged
from 2 to 10 years (mean 3,98±1,53; median 4,00) and
education ranged from 4 to 15 years (mean 5,08±2,31;
median 4,00). Results are shown on Table 1.
As shown in Table 2, there was a significant positi-
ve correlation between age and MMSE and SIB scores.
There was a significant negative correlation between
disease duration and MMSE and SIB scores and a pos-
itive correlation between disease duration and Bristol
scale. There was no correlation between education
or disease duration and these scores.
In Table 3 the values of correlation among the
scales are shown. There is a significant positive cor-
relation between MMSE and MMSEs and SIB and bet-
ween MMSEs and SIB. There is a significant negative
correlation between MMSE and Bristol scale. There
is a low but significant correlation between MMSEs
and Bristol and no correlation was found between
SIB and Bristol scale.
As shown in Table 4, and as expected, there is a
significant correlation between disease duration and
CDR, and between CDR and MMSE, MMSEs and SIB
score. On the other hand, no correlation was found
between CDR and age or education. Finally, as shown
in the dispersion graphic (Figure), there was a positi-
ve and significant correlation between both scales,
MMSE and MMSEs. 
DISCUSSION
As results have shown, both scales, MMSEs and
SIB, are more sensitive for the evaluation of severe
stage dementia patients than conventional screen-
ing scales like MMSE. With regard to MMSEs, Harrel
and cols11 have shown that it is comparable or even
superior to that of MMSE in this group of patients.
In a preliminary report Engelhardt and cols13, sug-
gested that MMSEs may give a better picture of
patients with very low traditional MMSE scores. 
There was no correlation between both scales and
education14,15. There is a large amount of research on
the correlation between education and cognitive per-
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Table 1. Means, standard deviation (SD), median and range of scores in the 50 patients.
Scale Mean SD Median Lower Higher
Mini-mental State Examination 9.48 2.96 10.00 3.00 14.00
Mini-mental State Examination-severe 23.66 4.01 25.00 15.00 29.00
Severe Impairment Battery 80.74 9.92 84.00 62.00 96.00
Bristol 28.64 7.91 28.00 11.00 46.00
Table 3. Spearman correlation and p value between the scales
in the 50 patients.
Scales
Scale MMSEs SIB Bristol
MMSE r 0.692 0.675 –0.445
p <0.001 <0.001 0.001
MMSEs r – 0.638 –0.289
p <0,001 0,042
SIB r – –0.270
p 0.058
r, Spearman correlation; p, significance level 5%.
Table 2. Spearman correlation coefficient, p value, age, disease
duration, and education in the 50 patients.
Scales
Variable MMSE MMSEs SIB Bristol
Age r 0.460 0.208 0.358 0.081
p 0.001 0.147 0.011 0.578
Education r –0.227 –0.124 –0.078 0.243
p 0.113 0.390 0.588 0.089
Disease r –0.382 –0.117 –0.478 0.497
Duration p 0.006 0.418 <0.001 <0.001
r, Spearman correlation; p, significance level 5%.
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Table 4. Values of means, square deviation, median with relation to age, disease duration, education and scales scores
according to CDR.
Variable CDR N Mean SD Median Lower Higher p*
Age 2 32 78.16 8.76 78.50 57.00 95.00 0.052
3 18 74.50 5.73 74.00 62.00 84.00
Education 2 32 4.84 2.53 4.00 4,00 15.00 0.057
3 18 5.50 1.86 4.00 4.00 8.00
Disease 2 32 3.66 1.29 3.00 2.00 8.00 0.038
duration 3 18 4.56 1.79 4.50 2.00 10.00
MMSE 2 32 11.25 1.72 12.00 8.00 14.00 <0.001
3 18 6.33 1.88 7.00 3.00 9.00
MMSEs 2 32 25.97 2.67 27.00 16.00 29.00 <0.001
3 18 19,56 2,33 19,00 15,00 23,00
SIB 2 32 85.88 6.15 86.50 66.00 96.00 <0.001
3 18 71,61 8,76 68,00 62,00 89,00
Bristol 2 32 26.53 7.16 26.50 11.00 41.00 0.013
3 18 32.39 7.97 31.00 20.00 46.00
*Mann-Whitney’s significance level.
Figure. Graphic correlation between MMSE and MMSEs.
formance, but our results could have two explana-
tions: the tasks in these two scales are quite simple
and there is a clear floor effect in control or less ad-
vanced dementia patients; the education bias might
disappear at a relatively early stage of dementias. 
The findings in our study suggest that MMSEs may
be useful in research and clinical practice, for the eva-
luation of severe dementia patients. There are metho-
dological and practical advantages, like the brief peri-
od of time for its application, a mean of 5 min, the
need of paper and pencil only, and the simple train-
ing that is required by the examiner. Additionally its
structure is similar to that of traditional MMSE, which
has a widespread popularity among health workers
dealing with dementia.
Howard and cols16 pointed that cognitive and
functional tools could and should be jointly used to
improve the clinical impression of the severe demen-
tia patient status in a more natural setting. On this
line of reasoning, co-variance analysis showed that,
though at a low level, there is a correlation between
MMSEs and Bristol scale, and it is possible to conclude
that this scale and what patient actually is in “real
life”. 
Ferraro and cols17, point to another aspect rele-
vant to this investigation, the need of standardizing
the creation and modification of tools for neuropsy-
chological evaluation, with regard to their inner struc-
ture and normative data that might de relevant to
other cultures. The same is suggested by Bell and
cols.18, when using cognitive batteries in Canada, and
reaching the conclusion that it is necessary to review
the characteristics of dementia progression, as a pre-
requisite to adapt these tools so that they become
more precise for more advanced stages.
The results of this investigation are in accordance
with those of other centers and meet a need of our
country with respect to the evaluation and follow up
of severe dementia patients. Considering that sur-
vival in dementia patients is increasing and new ther-
apies are being tried, this issue will become increas-
ingly crucial.
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